Purpose Truncation artefact (Gibbs ringing) causes central signal drop within vessels in pulmonary magnetic resonance angiography (MRA) that can be mistaken for emboli, reducing diagnostic accuracy for pulmonary embolism (PE). We propose a quantitative approach to differentiate truncation artefact from PE. Methods Twenty-eight patients who underwent pulmonary computed tomography angiography (CTA) for suspected PE were recruited for pulmonary MRA. Signal intensity drops within pulmonary arteries that persisted on both arterial-phase and delayed-phase MRA were identified. The percent signal loss between the vessel lumen and central drop was measured. CTA served as the reference standard for presence of pulmonary emboli.
Introduction
With recent hardware and software improvements, pulmonary magnetic resonance angiography (MRA) is emerging as an attractive alternative for detection of pulmonary embolism [1] [2] [3] [4] [5] . MRA can detect pulmonary embolism without radiation exposure or when computed tomography angiography (CTA) is contraindicated [6] . In the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) II study, up to 24 % of patients had a contraindication for CTA [7] . Despite the technical advances, the diagnostic quality of MRA images may be limited by different kinds of artefacts caused by patient motion, vascular flow, geometric distortions of the magnetic field, signal heterogeneity, aliasing, metallic implants, chemical shift, and signal truncation [8] [9] [10] . In particular, signal truncation artefact, or "Gibbs ringing", is observed as a distinct central signal intensity drop within the pulmonary vasculature in contrast-enhanced pulmonary MRA. If not recognized, this artefact may be mistaken as pulmonary embolism [2, 11, 12] . This is a particular concern for inexperienced MRA readers who are accustomed to reading pulmonary CTA images for detection of pulmonary embolism, where they are not confronted with this type of misleading artefact.
The truncation artefact is a ripple-like feature that appears near abrupt transitions between regions of high and low signal intensity. The truncation is caused by approximation errors in Fourier transform analysis, which is better used for estimating gradual transitions in tissue signal intensity. This approximation error is a fundamental property of practical Fourier imaging, because the underlying spectrum (kspace data) requires infinite sampling to accurately represent the object [13, 14] . "Truncation" of higher spatial frequencies produces erroneous oscillations in the signal intensity of pixels near high-contrast edges on the final image [1, [15] [16] [17] [18] (e.g. vessel lumen in contrastenhanced MRA). These may manifest as misleading single, central signal intensity dropouts in vessels 3-5 pixels in diameter such as lobar or segmental pulmonary arteries [2, 11] .
While pulmonary MRA demonstrates high accuracy for proximal pulmonary embolism, it shows only limited accuracy for distal pulmonary embolism and 30 % of inconclusive results [10] . In the PIOPED III study, causes of technically inadequate MRA were poor arterial opacification (67 %), motion (36 %), wraparound (4 %), and parallel imaging artefact (2 %) [9] . A recent study comparing MRA with CTA yielded good sensitivities for both readers (100 % and 86 %, respectively) but low specificities (55 % and 82 %, respectively). The authors attributed the high false positive rate (causing the low specificity) to truncation artefact [12] . In our clinical experience (>600 pulmonary MRA for diagnosis of pulmonary embolism over 6 years) we have observed that truncation artefact may be mistaken for emboli-or alternatively true emboli may be dismissed as artefacts-especially by inexperienced MRA readers (e.g. radiology residents or radiologists more familiar with CTA than with MRA). Therefore, the aim of our study was to establish an objective method that can help differentiate truncation artefact and true pulmonary emboli to improve the diagnostic performance of pulmonary MRA for diagnosis of pulmonary embolism.
Material and methods

Study population
This was a prospective single-institution Health Insurance Portability and Accountability Act (HIPAA) compliant and institutional review board approved study. We recruited 28 patients (15 female, 13 male; median age 52 years; range 21-91 years) with suspected pulmonary embolism who underwent clinical CTA to undergo a pulmonary MRA within 2 days following their CTA. Subjects were recruited between July 2010 and March 2013. Written informed consent was obtained from all patients. CTA and MRA were successfully performed in all 28 patients and all 56 data sets were included in the analysis. CTA demonstrated pulmonary embolism in 19 (68 %) of the 28 patients. The mean delay between CTA and MRA was 28±16 h.
CTA protocol
CT examinations were performed using a 64-slice MDCT (VCT, GE Healthcare, Waukesha, WI, USA) with a standard pulmonary CT angiography protocol: gantry rotation time 400 ms, collimation 64×1.25 mm, 0.686 pitch, tube voltage 120 kV. Effective tube current was automated, ranging from 100 to 400 mAs. One hundred millilitres of non-ionic iodinated contrast material with an iodine concentration of 300 mg/ml (Iohexol, GE Healthcare, London, UK) was injected at a rate of 4 ml/s via an 18-gauge antecubital peripheral intravenous catheter, followed by a 50-ml flush injected at the same rate. Fluoro-triggering at the level of the main pulmonary artery was used for determination of the contrast media bolus arrival time. The threshold level for triggering the image was achieved when the attenuation of the main pulmonary artery reached 100 Hounsfield units.
MRA protocol
All MRA studies were performed on a 1.5-T whole-body MR system (Signa HDxt, GE Healthcare, Waukesha, WI) with an eight-channel phased-array cardiac coil. Following acquisition of scout images, the MRA imaging protocol included pre-contrast, pulmonary arterial-phase, and immediate delayed-phase contrast-enhanced MRA using the same 3D T1-weighted spoiled gradient recalled echo MR angiography sequence [4] .
Each examination was performed during a single endexpiration breath-hold using the following parameters: repetition time/echo time (TR/TE) 2.9/1.0 ms (partial readout), average field of view 34×27×28-32 (SI×RL×AP), 256× 192×140-160 matrix, sagittal slab excitation, flip angle 28º, BW=±83 kHz, 1 signal average, elliptic centric k-space sampling, with k-space corner cutting in the k y -k z plane. True spatial resolution was 1.3×1.8×2.0 mm 3 , interpolated to 0.7× 0.7×1.0 mm 3 (512×512 matrix) by zero-filling. Parallel imaging was performed using a data-driven 2D parallel imaging method, (ARC, GE Healthcare) with an effective acceleration factor of approximately 3.6, slightly varying depending on the AP matrix size. The MRA acquisition combined a sagittal excitation slab combined with a coronal reconstruction to avoid phase wrap from the arms and shoulders [7, 19] . Imaging time varied depending on patient size and the field of view in the AP dimension (15-21 s) .
Contrast-enhanced images were acquired after injection of 0.1 mmol/kg of gadobenate dimeglumine (MultiHance™, Bracco Diagnostics, Princeton, NJ) diluted with saline to a total volume of 30 ml, injected at a rate of 1.5 ml/s. Pulmonary arterial-phase images were timed using fluoro-triggering, with examination initiation at the peak enhancement of the pulmonary artery. Using this approach, the examinations begin (i.e. centre of k-space is acquired) when the pulmonary arteries are fully opacified (typically 5-10 s following the start of injection) and the contrast bolus persists throughout the acquisition. The use of diluted contrast material injected over the entire acquisition time was found to be helpful in previous studies to avoid artefacts related to dynamic changes of the contrast during the acquisition [1, 9, 20] . All breath-hold images were acquired at end-expiration. Imaging in endexpiration reduces the chance of Valsalva manoeuvre causing transient interruption of the bolus [21] , reduces the volume of coverage (shorter breath-hold), and shows increased perfusion [22] . After the first acquisition (arterial phase) was finished and after the patient caught his or her breath, a second acquisition was performed (delayed phase).
Image analysis
MRA data sets were evaluated subjectively for the presence of central (i.e. without contact to the vessel wall) signal intensity drops within lobar and segmental pulmonary arteries that persisted on both arterial-phase and delayed-phase MRA images. Two radiologists (with 6 and 12 years of experience, respectively) performed a consensus reading in a randomized fashion, blinded to the results of the CTA. The presence and anatomical location (lobar or segmental) of each signal intensity drop within the pulmonary arteries was recorded, regardless of its appearance or probability of being truncation artefact or pulmonary embolism. The lung parenchyma associated with the signal intensity drops within the vessel lumen was assessed for the presence of perfusion defects. Signal intensity drops in the pulmonary trunk and in the main pulmonary arteries that clearly corresponded to large pulmonary emboli were excluded from analyses, since these did not represent a diagnostic dilemma. We also excluded all other signal drops in the vessels that subjectively did not represent a diagnostic dilemma. For example, only slight signal heterogeneity or signal intensity drops that extended outside the vessel lumen were excluded from the analysis.
For quantitative image analyses, the signal intensities of each area of central drop and of the surrounding vessel lumen were assessed on the arterial-phase and delayed-phase MRA images. A board-certified radiologist with fellowship training in cardiovascular MRI and 6 years of experience in diagnostic imaging measured the signal drop in the vessel lumen and the peak signal in the vessel lumen using multiplanar reformatted images. The signal intensity of the central drop (SI signal drop ) was obtained by taking the mean of three point measurements in the centre of the signal drop on three parallel slices oriented orthogonally to the vessel, skipping a slice between each measurement to minimize the effects of through-plane interpolation. The peak signal intensity of the surrounding vessel (SI vessel ) was measured on the same three slices by taking the mean of four single-point measurements taken around the central drop on each slice, totalling 12 measurements. The percent signal drop was calculated using (SI vessel −SI signal drop )/SI vessel ×100.
The reference for differentiating truncation artefact and pulmonary embolism was CTA. After analysis of the MRA images was complete, the CTA images and MRA images were unblinded. Each central vessel signal drop was characterized as either truncation artefact or true pulmonary embolism. Classification as artefact or embolus was determined by consensus by the same radiologists who had previously identified the central vessel signal drops on MRA.
Statistical analyses
The Mann-Whitney rank sum test for independent samples was used to test the significance of the difference between the percent signal drop of truncation artefacts and pulmonary emboli on arterial-phase and delayed-phase MRA images, respectively. The Wilcoxon rank sum test for paired samples was used to test the significance of the difference between arterial-phase and delayed-phase MRA images for both truncation artefacts and pulmonary emboli. The efficacy of percent signal drop as a test to differentiate truncation artefact from pulmonary embolism was evaluated using receiver operating characteristic (ROC) curve analysis for arterial-phase and delayed-phase MRA.
ROC curves were used to calculate the sensitivity and specificity with 95 % confidence intervals of obtained threshold values for correct identification of pulmonary embolism for both arterial-phase and delayed-phase MRA. Nonnormally distributed continuous variables are reported as median and ranges. P values less than 0.05 were considered statistically significant. Statistical analysis was performed with commercially available software (MedCalc Statistical Software version 12.7.5, MedCalc Software, Ostend, Belgium).
Results
A total of 65 central signal intensity drops were identified on both arterial-phase and delayed-phase MRA in the 28 subjects. A median of two signal intensity drops (range 1-3) were detected per patient. Eighteen (28 %) of the signal drops were located in lobar arteries and 47 (72 %) in segmental arteries.
Forty-eight out of 65 (74 %) of the signal drops were truncation artefacts and 17/65 (26 %) were true pulmonary emboli as confirmed on CTA. Thirty-four out of 48 (71 %) of the truncation artefacts were located in segmental arteries and 14/48 (29 %) were in lobar arteries. Fourteen out of 17 (82 %) of the pulmonary emboli were located in segmental arteries and 3 (18 %) were in lobar arteries (Table 1 ). An associated perfusion defect in the lung parenchyma was only observed in 7/17 (41 %) of the signal drops due to true pulmonary embolism. None of the 48 signal drops due to truncation artefact revealed an associated perfusion defect. Figure 1 shows an example of truncation artefact and pulmonary embolism located adjacent to each other in segmental arteries of the right lower lobe and demonstrating significantly different signal drops (24 % and 23 % for truncation artefact versus 78 % and 79 % for pulmonary embolism in arterial-phase MRA and delayed-phase MRA, respectively). The percent signal intensity drop ranged from 12 to 91 % during arterial-phase and from 11-89 % during delayed-phase MRA. During arterial-phase MRA, truncation artefacts had a significantly lower median signal drop of 26 % (range 12-58 %) compared to pulmonary emboli with 85 % (range 53-91 %) (p<0.0001). In delayed-phase MRA, truncation artefacts also revealed a significantly lower median signal drop of 26 % (range 11-55 %) as compared to pulmonary emboli with 77 % (range 47-89 %) (p<0.0001) (Fig. 2) . However, not all signal intensity drops of truncation artefact and pulmonary embolism showed such evident and marked differences, as illustrated in Figs. 3 and 4 . Figure 3 illustrates a case of truncation artefact with comparably large signal intensity drop in arterial-phase MRA (51 %), but relatively small signal drop in delayed-phase MRA (23 %). Figure 4 illustrates a case of pulmonary embolism with comparatively small signal drop in arterial-phase MRA (57 %) and in delayed-phase MRA (52 %).
When comparing arterial-phase and delayed-phase MRA, there was no significant difference between percent signal drop of truncation artefacts on arterial-phase MRA (26 %) and delayed-phase MRA (26 %) (p=0.522). In contrast, the percent signal drop of pulmonary emboli was significantly larger on arterial-phase MRA (85 %) than on delayed-phase MRA (77 %) (p<0.008).
ROC curve analysis revealed a slightly higher area under the curve (AUC 0.996, 95 % CI 0.938-1.000) on arterialphase MRA as compared to delayed-phase MRA (AUC 0.991, 95 % CI 0.929-1.000); however, this difference was not statistically significant (p=0.449) (Fig. 5) . On arterialphase MRA a threshold value of 51 % signal drop revealed an ROC curve derived sensitivity of 100 % (95 % CI 80.5-100 %) and specificity of 94 % (95 % CI 82.8-98.7 %) for correctly differentiating truncation artefact from pulmonary embolism. On delayed-phase MRA a threshold value of 47 % resulted in a sensitivity of 100 % (95 % CI 80.5-100 %) and specificity of 92 % (95 % CI 80.0-97.7 %) for correct differentiation of truncation artefact from pulmonary embolism (Fig. 6) . The sensitivity and specificity for other relevant threshold values are given in Table 2 . 
Discussion
In this study we have demonstrated that differences in percentage of signal intensity dropout can be used as an objective and quantitative tool to differentiate truncation artefact from pulmonary embolism in pulmonary MRA. ROC curve analysis derived a threshold value of 51 % signal intensity drop on first-pass MRA and 47 % on delayed-phase MRA for correct identification of pulmonary embolism with approximately 100 % sensitivity and greater than 90 % specificity. Our study shows that the observed percent signal drop for truncation artefact is significantly lower (26 %) than for true pulmonary embolism (85 % on arterial-phase and 77 % on delayed-phase MRA). However, our results also revealed that in some cases the measured signal drop of truncation artefact may be larger and that the signal drop of pulmonary embolism may be smaller than expected. This variability in central signal drop creates a potential diagnostic dilemma if an embolus is located centrally in the pulmonary artery (Fig. 4) . In some cases, the observed signal drop may have been exacerbated during the arterial phase because of suboptimal timing of the bolus relative to k-space sampling. If the contrast arrives in the pulmonary arteries during the middle of the examination, the centre of k-space is acquired when little or no contrast is present in the pulmonary artery and the edges of k-space are acquired when contrast is present. This leads to transient edge enhancement of the vessel periphery and central signal drop as first described by Maki et al. [1, 4, 5, 20] . This transient artefact could exacerbate the central signal drop on the arterial phase [20] . It is for this reason that the delayed phase should always be reviewed before a final diagnosis of pulmonary embolism is made.
The observation of pulmonary emboli with less signal intensity dropout might be caused by several factors. First, anticoagulant therapy was initiated in patients with pulmonary embolism prior to the MRA, and could alter the appearance of emboli on contrast-enhanced MRA compared to the appearance of a de novo MRA. Further, partial volume effects in smaller segmental vessels may reduce the measured signal intensity drop. We attempted to minimize these partial volume effects by using the mean of many single-point measurements instead of using a larger ROI. Finally, an inherent high T1 signal in a pulmonary embolus could reduce the apparent signal intensity drop.
We observed a significantly larger percent signal drop for pulmonary emboli in arterial-phase MRA as compared to delayed-phase MRA (85 % vs. 77 %). This is likely due to the decreased signal intensity of the surrounding contrastenhanced blood in the delayed-phase as compared to the arterial phase. Thus, the percentage of calculated signal intensity drop would be reduced, since the signal intensity of the emboli is unchanged. It is also possible that the smaller percent signal drop for pulmonary emboli in the delayed phase may be attributed to a slow contrast agent uptake of the pulmonary emboli. This could be related to partial lysis of the emboli during anticoagulation prior to the MRA, although this is speculative. Importantly, we observed no significant difference in the percent signal drop of truncation artefacts between arterial-phase MRA and delayed-phase MRA (both 26 %), which follows theoretical prediction that the signal intensity drop caused by truncation is a fixed percentage of the signal of the vessel lumen [11] . Hence, in borderline cases, the lack of change in the amount of signal drop between arterialphase and delayed-phase MRA would strongly favour truncation artefact and may be used as another criterion to differentiate between pulmonary embolism and truncation artefact.
The low signal drop of truncation artefact and the comparatively higher signal drop of pulmonary emboli in the pulmonary vasculature have been observed and anecdotally reported earlier by several groups [2, [8] [9] [10] [11] . These authors stated that truncation artefacts can be distinguished from true pulmonary emboli by relying on their central location and smaller signal drop [2, 11] . The quantitative and objective measurements of our study confirm these subjective reports and provide an objective approach to differentiate true emboli from artefact. 57 % and 52 % on arterial-phase and delayed-phase MRA, respectively. Of note, this embolus was the only one that was detected in this patient and could easily have been mistaken for a truncation artefact due to its central location within the vessel and relatively small signal intensity drop Differentiating truncation from pulmonary embolism is usually not a problem for experienced readers. This might be the reason why truncation artefact has not specifically been reported as a source of false positive results in large clinical trials [9] , but only recently in a smaller study performed by Kramer et al. [12] . However, for less experienced sites beginning to offer pulmonary MRA as an alternative to CTA for detection of pulmonary embolism, this is an important pitfall to avoid. On the basis of the results of our study, we recommend that quantitative evaluation be performed when there is difficulty determining whether central signal drop in a vessel represents a truncation artefact or a true pulmonary embolism. This approach can be used as an objective tool that can help correctly differentiate pulmonary embolism from truncation artefact with high accuracy. Signal intensity measurements should be performed for all equivocal signal drops. However, instead of using our optimal and partial volume minimizing technique, we recommend drawing one small ROI in the centre of the signal drop and one in the adjacent surrounding vessel lumen. For simplicity, we propose as a "clinical rule of thumb" the threshold value of 50 % signal intensity drop in pulmonary MRA for differentiating true pulmonary embolism from artefact.
Another practical approach in clinical practice is to look for peripheral wedge-shaped parenchymal perfusion defects in the arterial phase that are a secondary sign of true pulmonary embolism [1, 2, 10] . However, the amount of parenchymal enhancement is quite variable. Therefore, the utility of perfusion defects as a secondary sign of true embolism is limited only to those acquisitions in which overall parenchymal enhancement is sufficient to be able to detect a defect.
A potential technical approach to reducing confusion of truncation artefact with true embolism would be to change the resolution of the image. This would change the size of the vessels most affected by truncation artefact but would not affect signal drops due to true embolism. Unfortunately, increasing the resolution in order to shift the artefact to smaller vessels is not feasible because of the associated increased imaging time (i.e. breath-hold) and decreased SNR [8] . Retrospectively decreasing the spatial resolution in order to shift the artefact to larger vessels is a possibility; however, this is likely to also decrease the conspicuity of true emboli because of partial volume averaging.
The greatest limitation of this study is the potential lack of generalizability of our results to different injection protocols, contrast agents, spatial resolutions, MRI sequences, reconstruction algorithms, or MR platforms. All of these factors may affect the presence and more importantly the degree of signal drop and thereby the derived optimal threshold values. It is, however, reassuring that we observed very little overlap in the distribution of percent signal drop in truncation artefact and in true pulmonary embolism. This suggests that while the exact optimal threshold for differentiating truncation artefact from pulmonary embolism may vary depending on these various imaging parameters; there will likely be a useful threshold that will perform well for any given set of parameters. Another limitation of our study is the delay time between CTA and MRA. It is certainly possible that during the time between studies, new clots may have embolized to the lungs while some may have lysed. Further, the signal intensity of pulmonary emboli may have changed as a result of anticoagulation treatment and thrombolysis within the clot substance, possibly affecting the binding of gadolinium-based contrast. Fig. 6 Aligned dot plot analyses of percent signal drop and ROCderived threshold values. ROC analyses exhibited an ideal threshold of 51 % and of 47 % signal drop on (a) arterial-phase MRA and (b) delayed-phase MRA, respectively, with 100 % sensitivity and greater than 90 % specificity for differentiation of truncation artefact and pulmonary embolism Table 2 Threshold values with associated ROC curve-derived sensitivity and specificity values ranging from 100 % sensitivity to 100 % specificity for differentiation of truncation artefact and pulmonary embolism In summary, we have demonstrated the feasibility of using an objective approach for differentiating truncation artefact from pulmonary embolism with high accuracy. Truncation artefact could be differentiated from pulmonary embolism with high sensitivity (100 %) and specificity (greater than 90 %), when using a threshold of 51 % signal drop on arterial-phase or 47 % on delayed-phase MRA. By taking an objective approach to equivocal central signal drop, one will improve the diagnostic accuracy of pulmonary MRA for pulmonary embolism.
